3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1
3
Phase 3
2
Phase 1/2
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
31
Lung Neoplasms
9
Small Cell Lung Carcinoma
7
Biliary Tract Neoplasms
7
Carcinoma, Hepatocellular
6
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Carcinoma
4
Neoplasm Metastasis
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma Extensive Disease
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Non-Muscle Invasive Bladder Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Urothelial Cancer
1
Sarcoma
1
Radiation Pneumonitis
1
Pancoast Syndrome
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non Small Cell Lung Carcinoma NSCLC
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
durvalumab
×
Clear all
NCT07221253
2026-03-17
AB02
AstraZeneca
Phase 3
Recruiting
1,100 enrolled
NCT02369874
2021-02-10
EAGLE
AstraZeneca
Phase 3
Completed
736 enrolled
26 charts